论文部分内容阅读
目的观察持续低剂量疗法控制轻-中度哮喘患者的效果。方法选轻-中度哮喘患者50例,每天固定 FP 剂量为200μg/d,治疗14周。分别于治疗前、后进行肺功能检查、以及嗜酸粒细胞计数。结果治疗前患者的肺功能检查[呼气峰流速(379±74)L·min~(-1)、用力肺活量(3.89±0.89)L、第1秒用力呼气容积(FEV_1)(3.39±0.81)L]、使 FEV_1下降20%基础值的乙酰甲胆碱激发剂量(PD_(20))(102.40±18.40)μg及嗜酸粒细胞计数(0.19±0.07)%。治疗14周后,肺功能检查[(PEFR(346±111)L·min~(-1)、FVC(3.85±1.30)L、FEV_1(3.20±1.10)L]差异无显著性意义,P>0.05。而 PD_(20)值(835±398)μg及嗜酸粒细胞计数(0.43±0.05)%与治疗前相比,差异有统计学意义,P<0.05。结论用 FP 持续低剂量疗法治疗哮喘患者对改善 PD_(20)值和痰液嗜酸粒细胞计数具有良好的效果。
Objective To observe the effect of continuous low-dose therapy on patients with mild to moderate asthma. Methods Fifty patients with mild to moderate asthma were given a fixed daily FP dose of 200 μg / d for 14 weeks. Respectively before and after treatment for lung function tests, and eosinophil count. Results Before treatment, pulmonary function tests (peak expiratory flow rate (379 ± 74) L · min -1, forced vital capacity (3.89 ± 0.89) L, FEV 1 (3.39 ± 0.81 ) L], the methacholine challenge dose (PD_ (20)) (102.40 ± 18.40) μg and eosinophil count (0.19 ± 0.07)%, which decreased FEV_1 by 20% of the basal value. After 14 weeks of treatment, there was no significant difference in pulmonary function test (PEFR (346 ± 111) L · min -1, FVC 3.85 ± 1.30 L, FEV 1 3.20 ± 1.10 L], P> 0.05 (835 ± 398) μg and eosinophil count (0.43 ± 0.05)%, respectively, before treatment, the difference was statistically significant, P <0.05.Conclusion The treatment of asthma with sustained low dose FP therapy The patients have good effect on improving PD_ (20) value and sputum eosinophil count.